FDA — authorised 6 June 2017
- Application: NDA208630
- Marketing authorisation holder: NXDC
- Status: supplemented
FDA authorised Gleolan on 6 June 2017
Yes. FDA authorised it on 6 June 2017; FDA has authorised it.
NXDC holds the US marketing authorisation.